Zometa 4 mg / 5 ml, 1 vial (Zoledronic acid 4 mg / 5 ml) by Novartis.
Indications: Prevention of skeletal-related events in advanced malignancies involving bone; tumour-induced hypercalcaemia.
Administration: Intravenous infusion over at least 15 minutes, every 3–4 weeks.
Storage: Store below 25–30 °C in the original package. Keep out of the sight and reach of children.
Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only.
| Manufacturer | Novartis |
| Active ingredient | Zoledronic acid 4 mg / 5 ml — bisphosphonate. |
| Strength & pack | 1 vial of concentrate. |
| Form | Concentrate for solution for infusion |
| Storage | Store below 25–30 °C in the original package. Keep out of the sight and reach of children. |
| Regulatory status | Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only. |